our science

NAD+ is critically important to the function of all living cells. NAD+ levels have been shown to decline as humans age and research and preclinical models have demonstrated the broad therapeutic potential of increasing NAD+ to preserve health and normal metabolism.


OUR pipeline

Metro International Biotech boasts a novel drug development platform, producing first-in-class, small-molecule NAD+ enhancers that leverage the NAD+ cycle to treat rare diseases and pursue significant improvements in human health to combat the adverse conditions of aging. Metro International Biotech is initially targeting rare mitochondrial diseases.



Recent discoveries published in leading scientific and medical journals highlight the broad therapeutic potential of modulating NAD+ to treat a range of conditions.